Dr. Siner began his career investigating modulators of hyperoxic acute lung injury and performed translational research examining the role of circulating growth factors in the sepsis syndrome and their relationship to outcomes in the intensive care unit. He was the recipient of an F32 NIH National Research Service Award (NRSA) which supported his investigation of the role of VEGF and HO-1 in cytoprotection from hyperoxia induced acute lung injury. His has developed expertise in patient safety and quality in the domains of critical care and tele-medicine (Tele-ICU) and has several active projects to reduce adverse events from ICU readmissions and unexpected cardiac arrest. Active areas of research including improving implemenetation of low tidal volume ventilation (participant in multi-center RO1 investigating facilitators and barriers to LTVV and network effects) and a recently commenced multi-center RO1 investigating dysphagia after mechanical ventilation for acute respiratory failure. Through his leadership roles in the Tele-ICU and the Yale-New Haven Health System ICU Committee he is developing data tools to easily facilitate quality and safety improvements in the intensive care unit
Hospital Administration; Intensive Care Units; Pulmonary Medicine; Safety Management; Sepsis; Translational Research, Biomedical
| Conditions | Study Title |
|---|---|
| Diseases of the Respiratory Systems | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| Diseases of the Lung | Saracatinib (AZD0530) in the Treatment of Patients with Idiopathic Pulmonary Fibrosis |
| Women's Health; COVID-19 Inpatient; COVID-19 Outpatient | I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients |
| Diseases of the Blood; Infectious Diseases | Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) |